IntelliCell BioSciences, Inc. (“IntelliCell” or the “Company”), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced a license agreement for the indication of Diabetes Mellitus.
Invigorcell will be filing an IND with the FDA for the indication of Diabetes Mellitus.
According to Dr. Steven Victor CEO, “We are pleased to license the indication of Diabetes Mellitus to Invigorcell who will be conducting an IND with the FDA. With Joe Krivulka and Marc Sandberg MD leading the way I am sure we will see positive results with the FDA in a short period of time, and be able to change the lives of millions of diabetic patients.”
Marc Sandberg, M.D., “Diabetes has both a huge financial and personal burden around the world. Restoring both Beta Cell and Metabolic function using Stromal Vascular Fraction Cells derived from blood vessels found in adipose tissue has a great potential to relieve suffering of people and improve economies.”
Source: IntelliCell BioSciences
